



Canolfen Iechyd Genomig Cymru
Parc Busnes Ymyl Caerdydd
Eglwys Newydd
Caerdydd
CF14 7YU

Ffôn 📞 (029) 2184 2641

All Wales Medical Genomics Service
Wales Genomic Health Centre
Longwood Drive
Whitchurch
Cardiff
CF14 7YU

Reception 📞 (029) 2184 2641

12th May 2025

Dear Colleagues,

Germline BRCA1 and BRCA2 testing now available for **late stage breast cancer patients in relation to PARP inhibitor (Talazoparib and Olaparib) treatment decisions**

AWMGS are pleased to announce the availability of germline testing for BRCA1 and BRCA2 (for treatment and heredity reasons) and PALB2 (heredity only) for HER2-negative, locally advanced or metastatic breast cancer patients for whom PARP inhibitor treatment is an option if a (likely) pathogenic variant is identified in BRCA1 or BRCA2. This is panel R444.1 in the genomic test directory. This service will be implemented from the **12th May 2025**.

This testing can be requested using the updated version of the 'Breast Oncology genomic request form' (revision 3) which is now available on the AWMGS website: [AWMGS - Home \(medicalgenomicswales.co.uk\)](http://www.medicalgenomicswales.co.uk). Clinical guidance is also available on the NHS Wales Executive website via this link <http://executive.nhs.wales/functions/networks-and-planning/cancer/clinical-hub/genomics/>

If DNA was previously banked on a patient of yours before this service was available and this testing is still relevant for them then please contact the laboratory to activate testing (email: lab.genetics.cav@wales.nhs.uk and include 'FAO familial cancer section' in the title).

Please do not hesitate to contact us if you have any queries.

Yours sincerely,

Sheila Palmer-Smith

Principal Clinical Scientist
Familial Cancer section lead
All Wales Medical Genomics Service
Sheila.palmer-smith@wales.nhs.uk